OX40 Ligand

OX40 Ligand

OX40 Ligand Molekülinformation

Molecule Name
Tumor necrosis factor ligand superfamily member 4
Molekülalias
OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1,CD134 ligand,CD134L
Drug Development Progress
Anzahl der klinischen Arzneimittel13
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
CD134L,OX-40L,TNLG2B,OX4OL,GP34,CD252 Antigen,CD134 Ligand,TAX transcriptionally-activated glycoprotein 1,Tax-Transcriptionally Activated Glycoprotein 1, 34kD,CD252,OX40 ligand,OX40L,TNFSF4,Tumor necrosis factor ligand superfamily member 4,Glycoprotein Gp34,TNF Superfamily Member 4,TXGP1,Tax-Transcriptionally Activated Glycoprotein 1 (34kD),Tumor Necrosis Factor (Ligand) Superfamily, Member 4,Tumor Necrosis Factor (Ligand) Superfamily Member 4,Tumor Necrosis Factor Superfamily Member 4,Tumor Necrosis Factor Ligand 2B,OX40 Antigen Ligand
Molekülhintergrund
Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

OX40 Ligand Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
AmlitelimabKY-1005; SAR-445229Phase 3 ClinicalKymab Ltd, Sanofi
Alopecia Areata; Asthma; Celiac Disease; Dermatitis, Atopic; Eczema; Hidradenitis; Immune System Diseases; Lung Diseases, Interstitial; Scleroderma, Systemic
Details
APG-279APG279; APG-990/APG777Phase 2 ClinicalApogee Therapeutics Inc
Dermatitis, Atopic
Details
IMB-101 (IMBiologics)IMB-101 (IMBiologics); HDM-3019; IMB101 (IMBiologics); HDM3019; NAV-240Phase 2 ClinicalIMBiologics Corp
Arthritis, Rheumatoid; Hidradenitis Suppurativa
Details
IBI356IBI-356; IBI356Phase 2 Clinical
Autoimmune Diseases; Dermatitis, Atopic
Details
RP-3RP-3Phase 2 ClinicalReplimune Inc
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
HS-130HS-130Phase 1 ClinicalHeat Biologics
Solid tumours
Details
mRNA-2752mRNA-2752Phase 1 ClinicalAstrazeneca Plc, Moderna Inc
Lymphoma; Neoplasms; Solid tumours
Details
MQ-710MQ-710Phase 1 ClinicalImvaq Therapeutics Corp, Memorial Sloan Kettering Cancer Center
Adenocarcinoma, Sebaceous; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Hemangiosarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Paget Disease, Extramammary; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
OX-118OX-118Phase 1 ClinicalOxion Biologics AB
Autoimmune Diseases; Immune System Diseases; Rheumatic Diseases
Details
M-5542M5542; M-5542Phase 1 ClinicalMerck & Co Inc
Details
ABCL-575ABCL-575; ABCL575Phase 1 ClinicalAbCellera Biologics Inc
Dermatitis, Atopic
Details
APG-990APG-990; APG990; PR-007; PR007Phase 1 ClinicalParagon Therapeutics Inc
Dermatitis, Atopic
Details
SAR-443726SAR-443726Phase 1 ClinicalSanofi
Dermatitis, Atopic
Details